Odyssean LLC Invests $3.54 Million in Celldex Therapeutics, Inc. $CLDX

Odyssean LLC acquired a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 95,069 shares of the biopharmaceutical company’s stock, valued at approximately $3,538,000. Celldex Therapeutics makes up approximately 0.6% of Odyssean LLC’s portfolio, making the stock its 6th largest holding. Odyssean LLC owned about 0.12% of Celldex Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of CLDX. Russell Investments Group Ltd. grew its stake in Celldex Therapeutics by 27.6% in the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 501 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Celldex Therapeutics by 1.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company’s stock worth $798,000 after purchasing an additional 680 shares in the last quarter. ProShare Advisors LLC lifted its holdings in shares of Celldex Therapeutics by 6.9% during the 4th quarter. ProShare Advisors LLC now owns 11,973 shares of the biopharmaceutical company’s stock valued at $325,000 after buying an additional 773 shares during the last quarter. Handelsbanken Fonder AB lifted its holdings in shares of Celldex Therapeutics by 5.0% during the 2nd quarter. Handelsbanken Fonder AB now owns 27,200 shares of the biopharmaceutical company’s stock valued at $1,012,000 after buying an additional 1,300 shares during the last quarter. Finally, Panagora Asset Management Inc. grew its stake in shares of Celldex Therapeutics by 7.5% in the 4th quarter. Panagora Asset Management Inc. now owns 21,856 shares of the biopharmaceutical company’s stock valued at $594,000 after buying an additional 1,522 shares in the last quarter.

Celldex Therapeutics Stock Up 0.8%

Shares of Celldex Therapeutics stock opened at $39.68 on Friday. The stock has a market capitalization of $3.12 billion, a P/E ratio of -9.12 and a beta of 0.84. The stock has a 50 day moving average price of $39.07 and a two-hundred day moving average price of $33.80. Celldex Therapeutics, Inc. has a 12-month low of $22.10 and a 12-month high of $45.14.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.12. The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.73 million. Sell-side analysts anticipate that Celldex Therapeutics, Inc. will post -4.13 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on CLDX shares. Canaccord Genuity Group dropped their price objective on Celldex Therapeutics from $62.00 to $60.00 and set a “buy” rating on the stock in a report on Wednesday, July 22nd. Cantor Fitzgerald decreased their target price on shares of Celldex Therapeutics from $67.00 to $61.00 and set an “overweight” rating for the company in a research report on Wednesday, July 22nd. Guggenheim boosted their target price on shares of Celldex Therapeutics from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Monday, July 20th. Wells Fargo & Company increased their price target on shares of Celldex Therapeutics from $48.00 to $72.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Finally, UBS Group raised their price target on shares of Celldex Therapeutics from $38.00 to $45.00 and gave the company a “buy” rating in a report on Wednesday, June 10th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $56.08.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.